APLS
NASDAQ · Biotechnology
Apellis Pharmaceuticals Inc
$41.03
-0.03 (-0.07%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+64.32%
1Y
+120.47%
YTD
+58.66%
Open$41.05
Previous Close$41.06
Day High$41.07
Day Low$41.03
52W High$41.14
52W Low$16.83
Volume—
Avg Volume11.48M
Market Cap5.25B
P/E Ratio39.41
EPS$1.00
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$23.47
Above
SMA 200
$22.25
Above
RSI (14)
47.9
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Hold
27 analysts
Price Target
-45.1% upside
Current
$41.03
$41.03
Target
$22.54
$22.54
$12.93
$22.54 avg
$29.12
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.02B | 3.03B | 2.81B |
| Net Income | 22.72M | 93.04M | 81.85M |
| Profit Margin | 2.2% | 3.1% | 2.9% |
| EBITDA | 57.83M | 115.17M | 115.66M |
| Free Cash Flow | — | 42.87M | 48.47M |
| Rev Growth | +137.0% | +21.3% | +20.6% |
| Debt/Equity | 1.23 | 0.57 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |